




Chronic forms of coronary artery disease

Sepši Milan
sepsim@gmail.com

University Hospital Brno, Department of Internal Medicine and Cardiology



CAD is the first cause of death



Murray & Lopez. Lancet. 1997;349:1269-1276



Pathophysiology


Vascular resistance

(metabolic control, humoral and neural factors)

Coronary blood flow

(duration of diastole / pressure gradient)

Oxygen demand



Oxygen supply

- Heart rate
- Contractility
- Systolic wall stress




Timeline

Foam Cells



Complicated Lesion/
Rupture



Endothelial Dysfunction

From First Decade


From Third Decade

From Fourth Decade



Diagnosis

History of patient



Risk assessment (low, probable, high)



Estimate of CAD Probability (Duke Clinical Score)



Estimate of CAD Probability

- a 60-year-old man with a history of myocardial infarction has
- a 94 % likelihood of having significant CAD
- a 32-year-old woman with nonanginal chest pain has
- a 1 % chance of CAD



Risk factors

- Major independent risk factors

- Adva
- Toba
- Diabe
- Eleva
- Hype

- Condition


- Eleva
- Inflar
- Proth
- Smal

- Predispos

- Abdo
- Ethni
- Fami
- Obes
- Psyc



Atherosclerosis:
a multifactorial disease



Angina pectoris

- Typical angina (definite)

- 1. Characteristic quality
- 2. Rest and
- 3.

- Atypical

- M


- Nonc

- M

fort in the
as caused by
to the heart
muscle.



Pain - description




the pain



Stable / Unstable angina

- Stable: duration > 60 days



na

in severity

- the acute coronary syndromes of unstable angina and non-ST-segment elevation myocardial infarction were linked
- Now. ACUTE CORONARY SYNDROME



Silent ischemia

- A silent ischemic episode is an episode of myocardial ischemia that is not associated with chest pain or other symptoms
- It is estimated that 40 percent of patients with a history of myocardial infarction have silent ischemia
- Silent ischemia is often detected on ECG monitoring
- Pathophysiology of Silent Ischemia: neuropathy (diabetic patients) or less severe ischemia?



Diagnosis – tests I.

- Resting 12 lead ECG (normal in 50% pts)



- Ech



Name: stp QIMDS

HR: 57 BPM

Axis: -11 <

QRS: 93 ms


QTc: 470

PQ: 267 ms

RV5+SV1: 18.8mm

Comments:

M.D.



Name: QS AL

HR: 80 BPM

Axis: -6 °

QRS: 80 ms

QTc: 400

PQ: 203 ms

RV5+SV1: 8.3mm

Comments:

M.D.



Name: LBBB 2

HR: 65 BPM

Axis: -13 <

QRS: 137 ms


QTc: 470

PQ: 187 ms


RV6+SV1: 30.7mm

Comments:

M.D.



Echocardiography – anterior wall




Courtesy of:
MUDr. Jan Maňoušek



Diagnosis – tests II

Exercise ECG stress testing



grip

- dobutamine

in one or more LV segments with

stress



- (2) diminution in systolic wall thickening in one or more segments during stress, and
- (3) compensatory hyperkinesis in complementary (nonischemic) wall segments

Myocardial Perfusion Imaging

- thallium -201 (^{201}Tl); technetium-99m ($^{99\text{m}}\text{Tc}$)
- single-photon emission computed tomography (SPECT)



8:48




Jan Burda
Date of Birth: 01.01.1948 (57 y.)
Male, 174 cm, 83.0 kg

EXERCISE TEST / Stored ECG
Patient ID 480101/440

HELLIGE CardioSoft V2.51


Page 3

Page 1



Comparison of Stress Tests

- meta-analysis on 44 articles (published between 1990 and 1997)



exercise echocardiography had significantly better discriminatory power than exercise myocardial perfusion imaging



Diagnosis – coronary angiography

•




iliar

•

n whom





Chronic Stable Angina

Treatment Objectives

- To reduce the risk of mortality and morbid events
- To reduce symptoms
 - anginal chest pain or exertional dyspnea
 - palpitations or syncope
 - fatigue, edema or orthopnea



Treatment

- Non – pharmacological




Nitroglycerin / nitrates

- (Calcium – antagonist)



Indications of revascularisation

1. To be candidate for revascularization procedure, one must have evidence of significant stenosis of ischemia.



2. Indications for **Intervention** (PCI) and **Coronary Bypass Graft** (CABG) may vary from one center to another according to experience, skills and results.


3. Definite indications for **CABG**: 3 VD with proximal stenosis, LM disease.

4. Definite indications for **PCI**: SVD (apart from ostial LAD), favourable morphology .






Procedure

- Sheath in femoral, radial or brachial artery
- diameter sheath (usually 6F, but also 5 to 8)
- guiding catheter
- guide wire 0.014 inch
- balloon
- stent



PCI - ACD





ide by harvesting
 ching it between

ery from its
 normal course and attaching it to the coronary artery

- Internal Mammary Artery
- Gastroepiploic Artery
- Radial Artery



Current Medical State of SVG Disease

- Average lifespan of SVGs is 5-10 years
 - 50% of SVGs will fail within 10 years
 - 75% will fail within 15 years of the same period
- SVG lesions pre and post surgery are typically caused by intimal hyperplasia
 - respond to medical therapy
- Late vein graft stenoses are more commonly caused by diffuse atherosclerosis
 - friable plaque and thrombus tend to fragment and embolize into distal coronary vessels



Ischemia Trial 2019

Patients with **stable** ischemic ischemic heart disease and moderate to severe ischemia were randomized to routine medical therapy (n = 1,588) versus **optimal medical therapy** (n = 1,588).

Duration


Mean patient age: 64 years

Inclusion: Moderate to severe ischemia on noninvasive stress testing

Presented by Judith S. Hochman at the American Heart Association Annual Scientific Sessions (**AHA 2019**), Philadelphia, PA, November 16, 2019.



Ischemia Trial



medicines and lifestyle changes alone.



Treatment

- Non – pharmacological
 - Revascularisation: CABG / PCI
 - heart transplantation
- Pharmacological
 - antiplatelet agents
 - Betablockers
 - ACEI
 - Calcium – antagonist
 - Lipid lowering agents
 - Nitroglycerin / nitrates



Treatment – antiplatelet agents

Cyclooxygenase inhibitors

- Aspirin (Acetylsalicylic acid) 100 mg daily

Adenosine (AT₂) receptor inhibitors 6-

- Ticagrelor
- Prasugrel
- Clopidogrel 75 mg daily
- (Ticlopidine)



Treatment - betablockers

- Cardioselective

- Metoprolol: 100-400 mg

-

- (long half-life)

- With sympathomimetic activity

-

- mg

- No (no α -blocking activity)

-



Treatment - betablockers

- Freemantle Nick, et al: **β Blockade after myocardial infarction: systematic review and meta regression analysis** BMJ 1999;318:1730

- Systematic review of randomised controlled trials.


- **Subjects:** Patients

- **Intervention:**

- **Main:** outcome reinfarction

- We identified a 25% reduction in the odds of death in long term trials (95% confidence interval 15% to 31%)





- Bangalore S, Steg G, Deedwania P, et al; REACH Registry Investigators. JAMA. 2012;308(13):1340-1349



Treatment : lipid lowering agents

Tab. 4 Metaanalýza studií – kvantifikace účinku statinů⁴

	Denní dávka statinu				
	5 mg	10 mg	20 mg	40 mg	80 mg
a) Absolutní pokles (mmol/l) LDL cholesterolu v séru					
Simvastatin	1.0	1.5	2.0	2.5	3.0
Lovastatin	1.0	1.5	2.0	2.5	3.0
Pravastatin	1.0	1.5	2.0	2.5	3.0
Fluvastatin	1.0	1.5	2.0	2.5	3.0
Atorvastatin	1.0	1.5	2.0	2.5	3.0
Rosuvastatin	1.0	1.5	2.0	2.5	3.0
b) Procentuální pokles (%) LDL cholesterolu v séru					
Simvastatin	23	27	32	37	42
Lovastatin		21	29	37	45
Pravastatin	15	20	24	29	33
Fluvastatin	10	15	21	27	33
Atorvastatin	31	37	43	49	55
Rosuvastatin	38	43	48	53	58

Barevně jsou vyznačeny ekvipotence dle Wenga a spol., 2010.⁵ Dávky statinů schopné snížit LDL cholesterol zhruba o 20–30 % jsou označeny bíle a dávky schopné snížit LDL cholesterol zhruba o 30–40 % jsou označeny tmavě zeleně.

Tab. 1 Cílové hodnoty cholesterolu a apolipoproteinu B

	Populace obecně	Bez KVO, riziko $\geq 5\%$, DM2 nebo DM1 s mikroalbuminurií	Přítomnost KVO
Celkový	< 5 mmol/l	< 4.5 mmol/l	< 4.0 mmol/l

Podle: Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti⁶

Tab. 2 Optimální hodnoty HDL cholesterolu a triglyceridů (stejně pro všechny kategorie rizika)

	Muži	Ženy
HDL cholesterol	$> 1,0$ mmol/l	$> 1,2$ mmol/l
Triglyceridy	$< 1,7$ mmol/l	$< 1,7$ mmol/l

Podle: Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti⁶



Treatment - nitrates

- tolerance is a problem
- nitroglycerin spray (Aborts acute hypertension)
- nitroglycerin SL
- nitroglycerin 0.25 mg/h patches Prophylactic
- nitroglycerin 0.50 mg three times daily
- nitroglycerin 20 mg twice daily Take with food
- nitroglycerin 10 mg form – once daily
- nitroglycerin (vasodilators)




Treatment : ca blockers

- Calcium Channel Blockers:
 - Heart Rate Lowering
 - Verapamil 120–480mg Heart-rate lowering; AV block, heart failure, constipation
- Dihydropyridine Calcium Channel Blockers
 - Amlodipine 5–10mg Least myocardial depression
 - Felodipine 5–20mg High vascular selectivity



Alternative Diagnoses to Angina for Patients with Chest Pain

Myocardial infarction, pericarditis



fracture
shingles

gastroesophageal reflux
gastrocholelithiasis, cholangitis



Variant (Prinzmetal's) angina

vessels

during coronarography

=ergometrine intra arterially)

(verapamil)



Cíle po IM – sekundární prevence

- Zánětlivé markery
- Koncentrace glukózy
- Redukce tlaku
- TK < 130/80 mmHg
- TCF < 5 mmol/l
- LDL < 2,6 mmol/l
- TG < 1,7 mmol/l, HDL > 1 (1,2 ženy) mmol/l



Treatment

A = Aspirin and Antianginal therapy

B =)

C =

D =


E =

•Th

•Th
•Th
•Th
•Th



CAD with heart failure



CAD with heart failure

- Diagnosis: echo, CT scan



Arrhythmias - supraventricular


Atrial fibrillation



01-Dec

07:14:30

07:15:00



07:19:30

07:20:00

07:20:30

07:21:00

07:21:30

07:22:00

07:22:30

07:23:00

07:23:30


07:24:00

07:24:30

07:25:00

07:25:30

07:26:00



VE Run Length 20 beats (195 bpm) 01-Dec-2009 07:19:03

126 BPM at cursor



Sudden death

heart disease



Thank You for You attention!

